Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

Maria-Victoria Mateos,1 Andrew Spencer,2 Ajay K. Nooka,3 Ludek Pour,4 Katja Weisel,5 Michele Cavo,6 Jacob P. Laubach,7 Gordon Cook,8 Shinsuke Iida,9 Lotfi Benboubker,10 Saad Z. Usmani,11 Sung-Soo Yoon,12 Nizar J. Bahlis,13 Christopher Chiu,14 Jon Ukropec,15 Jordan M. Schecter,16 Xiang Qin,14 Lisa O’Rourke,14 and Meletios A. Dimopoulos17

1University Hospital of Salamanca/IBSAL, Salamanca, Spain; 2Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia; 3Winship Cancer Institute, Emory University, Atlanta, GA, USA; 4University Hospital Brno, Brno, Czech Republic; 5University Medical Center of Hamburg-Eppendorf, Hamburg, Germany; 6Institute of Hematology Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 7Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 8St James’s Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom; 9Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; 10Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France; 11Levine Cancer Institute/Atrium Health, Charlotte, NC, USA; 12Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea; 13Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada; 14Janssen Research and Development, LLC, Spring House, PA, USA; 15Janssen Global Medical Affairs, Horsham, PA, USA; 16Janssen Research & Development, LLC, Raritan, NJ, USA and 17National and Kapodistrian University of Athens, Athens, Greece

©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.217448

Received: January 23, 2019.
Accepted: June 20, 2019.
Pre-published: June 20, 2019.
Correspondence: MARIA-VICTORIA MATEOS - mvmateos@usal.es
Supplemental Appendix.

Supplemental Table 1. MRD-negative status (10^{-5} sensitivity threshold) according to an age-based analysis in POLLUX and CASTOR among patients who received 1 prior line of therapy.

|                  | POLLUX |                      | CASTOR |                      |
|------------------|--------|----------------------|--------|----------------------|
|                  | ITT    | 65-74 years          | ≥75 years | 65-74 years          | ≥75 years |
| MRD, n (%)       |        |                      |        |                      |
| D-Rd             | D-Rd   | Rd                   | P value | D-Rd                | Rd       |
| (n=149)          | (n=62) | (n=146)              |        | (n=17)              | (n=16)   |
| D-Rd             |         |                      |        |                      |
| Rd               |         |                      |        |                      |
| (n=146)          | (n=59) |                      |        |                      |
| P value          |        |                      |        |                      |
| Sensitivity threshold, 10^{-5} | 38 (25.5) | 12 (8.2) | 0.000053 | 15 (24.2) | 5 (8.5) | 0.017519 |
| Vd               |         |                      |        |                      |
| (n=122)          | (n=113)|                      |        |                      |
| P value          |        |                      |        |                      |
| Sensitivity threshold, 10^{-5} | 17 (13.9) | 3 (2.7) | 0.001138 | 9 (19.1) | 1 (2.6) | 0.011285 |

MRD, minimal residual disease; ITT, intent-to-treat; D-Rd, daratumumab/lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; D-Vd, daratumumab/bortezomib/dexamethasone; Vd, bortezomib/dexamethasone.
Supplemental Table 2. MRD-negative status (10^{-4} and 10^{-6} sensitivity thresholds) according to an age-based analysis of patients in POLLUX and CASTOR.

**POLLUX**

| MRD, n (%) | 65-74 years | ≥75 years | 65-74 years | ≥75 years |
|------------|-------------|-----------|-------------|-----------|
|            | D-Rd (n=286) | Rd (n=283) | P value     | D-Rd (n=124) | Rd (n=108) | P value | D-Rd (n=29) | Rd (n=35) | P value |
| Sensitivity threshold | | | | | | | | |
| 10^{-4}     | 97 (33.9) | 28 (9.9) | <0.000001 | 37 (29.8) | 13 (12.0) | 0.000793 | 11 (37.9) | 2 (5.7) | 0.001029 |
| 10^{-6}     | 37 (12.9) | 8 (2.8) | 0.000003 | 17 (13.7) | 3 (2.8) | 0.001811 | 1 (3.4) | 2 (5.7) | 0.665621 |

**CASTOR**

| MRD, n (%) | 65-74 years | ≥75 years | 65-74 years | ≥75 years |
|------------|-------------|-----------|-------------|-----------|
|            | D-Vd (n=251) | Vd (n=247) | P value     | D-Vd (n=96) | Vd (n=87) | P value | D-Vd (n=23) | Vd (n=35) | P value |
| Sensitivity threshold | | | | | | | | |
| 10^{-4}     | 47 (18.7) | 9 (3.6) | <0.000001 | 25 (26.0) | 3 (3.4) | 0.000006 | 3 (13.0) | 0 | 0.016014 |
| 10^{-6}     | 12 (4.8) | 2 (0.8) | 0.004763 | 6 (6.3) | 1 (1.1) | 0.057414 | 0 | 0 | N/A |

MRD, minimal residual disease; ITT, intent-to-treat; D-Rd, daratumumab/lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; D-Vd, daratumumab/bortezomib/dexamethasone; Vd, bortezomib/dexamethasone; N/A, not available.

*a*Based on the ITT analysis set.